Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan
June 18, 2019 09:05 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight, and follow...
Progenics to Mail Letter to Shareholders
June 13, 2019 17:00 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
June 13, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting
June 06, 2019 07:45 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma
June 03, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
- Long-Term Follow Up Data from Pivotal Study Presented at ASCO -- Patients Treated with AZEDRA Show Overall Survival of 73.1% at Two Years and 44.2% at Four Years - NEW YORK, June 03, 2019 (GLOBE...
Progenics Pharmaceuticals Mails Letter to Shareholders
June 03, 2019 08:00 ET
|
Progenics Pharmaceuticals Inc.
Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics”...
Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
May 30, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
May 23, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404
May 14, 2019 08:30 ET
|
Progenics Pharmaceuticals Inc.
NEW YORK & DRESDEN, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
May 09, 2019 07:45 ET
|
Progenics Pharmaceuticals Inc.
AZEDRA® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat PatientsPhase 2 Trial of 1095...